CClinicalTrials.gg
RecruitingNCT06682286Updated May 11, 2025

Assessment of Breathing Pattern During NIV

An interventional study of NIV mask A and NIV mask B in COPD (Chronic Obstructive Pulmonary Disease) and Obesity Hypoventilation Syndrome (OHS), sponsored by Fisher and Paykel Healthcare. Recruiting at 1 site in New Zealand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-11.

Sponsored by Fisher and Paykel Healthcare · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

COPD and OHS are respiratory conditions that disrupt normal breathing. Positive airway pressure, specifically Non-Invasive Ventilation (NIV), has been shown to improve breathing and reduce symptoms in patients with these conditions. Regular use of NIV can lead to better symptom management, improved quality of life, and reduced use of healthcare resources. The type of mask used for breathing support can greatly affect a patient's comfort and willingness to use it. For conditions like Obstructive Sleep Apnea (OSA), which is a physical blockage of the airway caused by the relaxation of the muscles of the throat, nasal masks are often used because they are comfortable and work well. But for breathing support in the hospital, full face masks are typically used because patients are having significant trouble breathing and tend to breathe through their mouth.

However, it's important to note that we don't yet fully understand the best way to provide breathing support for long-term NIV users, like COPD and OHS patients. The understanding of breathing route is currently only established for OSA. However, conditions like COPD affect the lungs and the overall system used for breathing, which is different from the throat blockage seen in OSA. So, the assumptions we make based on conditions like OSA may not apply to these other conditions. More research is needed to understand this better.

Read the detailed description
  • Participants undergo PSG, lying on their backs while their breathing route is recorded for about 30 minutes.
  • The participants are then put on their prescribed airway pressure support with the first randomized mask, and their breathing is recorded again for 30 minutes.
  • The mask is switched to the second mask, and the same procedure is repeated.

Participants are then moved to the sleep laboratory for the night where they are provided with beds.

  • They continue NIV therapy with the last mask used during the awake test.
  • After at least 60 minutes of recording, participants are awakened to switch back to the first mask. They are then allowed to sleep uninterrupted for the rest of the night.
02

Conditions studied

  • COPD (Chronic Obstructive Pulmonary Disease)
  • Obesity Hypoventilation Syndrome (OHS)
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age over 18 years
  • Prescribed nocturnal NIV for COPD or OHS
  • Able to complete an overnight sleep study
  • Comfortable to sleep on a standard double bed
  • Capacity to complete informed consent

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled sleep apnea (Apnea-hypopnea index (AHI) over 15 events/hour off personal NIV device data)
  • Prescribed IPAP above 25 cmH2O
  • Self-reported pregnancy
  • Allergic to adhesive of the sensors
  • Self-reported cold/flu symptoms
04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • No intervention
    Breathing route assessment: Awake and off pressure support

    Breathing route will be recorded in awake participants without the use of NIV for approximately 30 min.

  • Experimental
    Breathing route assessment: Awake and on pressure support

    Awake participants will be placed on their prescribed pressure support settings and will use two different non-invasive ventilation (NIV) masks, each for about 30 minutes.

    Other: NIV mask A · Other: NIV mask B

  • Experimental
    Breathing route assessment: Asleep and on pressure support

    Participants will be placed on their prescribed pressure support settings and will go to sleep. After 60 minutes, they will be awakened to change their mask. They will use two different non-invasive ventilation (NIV) masks, each for a minimum of 60 minutes

    Other: NIV mask A · Other: NIV mask B

Interventions

  • OtherNIV mask A

    Bridge free face mask

  • OtherNIV mask B

    Full face mask

05

What researchers measure

Primary outcomes

  1. Breathing route while on and off pressure support (awake)

    Percent of time nose and mouth breathing in COPD and/or OHS patients while on and off pressure support.

    Time frame: 4 hours

  2. Breathing route while on pressure support (asleep)

    Percent of time nose and mouth breathing in COPD and/or OHS patients while on pressure support during sleep.

    Time frame: 8 hours

  3. Mask type influence on breathing route (asleep and awake)

    Percent of time nose and mouth breathing in COPD and/or OHS patients depending on the NIV mask type

    Time frame: 12 hours

06

Study locations

1 of 1 sites recruiting
  • Fisher and Paykel Healthcare Sleep Laboratory
    Auckland, 2013, New Zealand
    • Jessica Fogarin · Contact · jess.fogarin@fphcare.co.nz · 7327
    • Valeria Mereacre · Sub investigator
    • William R Good, Medical degree · Principal investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06682286
Lead sponsor
Fisher and Paykel Healthcare
Responsible party
Sponsor
First posted
Nov 12, 2024
Start date
Jan 24, 2025
Primary completion
Sep 2025 (estimated)
Completion
Sep 2025 (estimated)
Last update
May 11, 2025

Study contacts

Valeria Mereacre, PhD Physiology
Contact
val.mereacre@fphcare.co.nz
0064 2102819036
Jessica Fogarin
Contact
jess.fogarin@fphcare.co.nz
William Good, Medical degree
principal investigator · Middlemore Hospital, New Zealand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion